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Summary
High content imaging combines automated microscopy with image analysis approaches to simultaneously 
quantify multiple phenotypic and/or functional parameters in biological systems. The technology has 
become an important tool in the fields of safety sciences and drug discovery, because it can be used  
for mode-of-action identification, determination of hazard potency and the discovery of toxicity targets 
and biomarkers. In contrast to conventional biochemical endpoints, high content imaging provides 
insight into the spatial distribution and dynamics of responses in biological systems. This allows the 
identification of signaling pathways underlying cell defense, adaptation, toxicity and death. Therefore, 
high content imaging is considered a promising technology to address the challenges for the  
“Toxicity testing in the 21st century” approach. Currently, high content imaging technologies are 
frequently applied in academia for mechanistic toxicity studies and in pharmaceutical industry  
for the ranking and selection of lead drug compounds or to identify/confirm mechanisms underlying 
effects observed in vivo. A recent workshop gathered scientists working on high content imaging  
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1  Introduction
the term high content imaging (HCI) is used to describe auto-
mated microscopy combined with image analysis approaches to 
simultaneously quantify multiple phenotypic and/or functional 
parameters in biological systems (Giuliano et al., 1997, 2003; 
Abraham et al., 2004). typically, multiple morphological (e.g., 
cell shape, membranes, nuclei, mitochondria) or functional (e.g., 
signal transduction, gene expression, metabolism) features in 
either a cell, cell system or lower model organism are labeled 
using probes (e.g., fluorescent dyes, antibodies, gene reporters), 
automatically imaged and quantified by imaging analysis algo-
rithms. Assessment of multiple biological parameters in individ-
ual cells may lead to more insight into the mechanistic effects of 
compounds. HCI technologies can also be used for the design of 
screening assays, with the purpose of testing large numbers of 
compounds for a limited set of biological parameters to identify 
hits for further mechanistic studies (Buchser et al., 2004). 
HCI has become an important tool in the field of safety sci-
ences, because it can be used for mode-of-action (MoA) iden-
tification, hazard potency determination and the discovery of 
predictive biomarkers for the mechanistic safety assessment of 
compounds (Young et al., 2008; Zanella et al., 2010). In contrast 
to conventional biochemical endpoints that provide quantitative 
information on a biological readout(s) at a given time-point, 
HCI of multiple read-outs in living cells can provide insight into 
the spatial distribution and dynamics of responses in biological 
systems over time (Massoud and Gambhir, 2003). the mode-
ling of these dynamic responses across dose and time allows the 
identification of signaling pathways underlying cellular defense, 
adaptation, toxicity and death (Mohamed et al., 2011; Herpers 
and van de Water, 2013; Wink et al., 2014). therefore, HCI is 
considered a promising technology to address the challenges 
laid out in Toxicity Testing in the 21st Century: A Vision and a 
Strategy (NRC, 2007; leist et al., 2008; Andersen and Krewski, 
2009; Berg et al., 2011; van Vliet et al., 2011).
Research based on HCI technologies has provided insight 
into toxicity mechanisms for different target organs, such as 
hepatotoxicity (Kim et al., 2012; latta et al., 2000; Persson et 
al., 2013; trask et al., 2014), neurotoxicity (leist et al., 2012; 
Schildknecht et al., 2013; lotharius et al., 2005; Dragunow, 
2008; Stiegler et al., 2011; Harrill et al., 2013; Krug et al., 2013) 
and cardiotoxicity (Kim et al., 2011; Földes and Mioulane, 
2013). Moreover HCI has been used to study and understand 
the biological mechanisms involved in stem cell differentiation 
or inflammatory signaling (Barbaric et al., 2010; Henn et al., 
2009, 2011; Sherman et al., 2011; Kuegler et al., 2012). In the 
pharmaceutical industry, tailored HCI assays are used for the 
ranking and selection of lead drug compounds and to identify or 
confirm a mechanism for an observed in vivo effect. the high 
content screening of drug lead compounds in human cell sys-
tems has been shown to generate relevant data to support the 
decision making process (O’Brien et al., 2006; Abraham et al., 
2008; tolosa et al., 2012). 
Because of the increasingly important role of HCI in safety 
sciences and drug development, a workshop was organized in 
Mainz, Germany on October 21-23, 2013. expert scientists from 
academia, pharmaceutical industry and regulatory organizations 
were invited to discuss the current and future role of HCI tech-
nologies in safety sciences and drug development. On the first 
day, the scientists presented state-of-the-art HCI studies and dis-
cussed the status quo of the technology in their different institu-
tions. On the second day, technical and methodological gaps, the 
need for quality control and performance standards and the fu-
ture requirements for implementation into the regulatory frame-
work were discussed. this report aims to summarize the main 
outcomes and recommendations of the workshop and to facilitate 
a wider discussion and collaboration within the field to advance 
the technology and bring it closer to the regulatory context. 
2  High content imaging approaches: status quo 
2.1  Characteristics and added value of  
the high content imaging approach
High content imaging is particularly useful for safety sciences 
and drug development because it can generate different types 
of biological, toxicological and pharmacological information 
that support the interpretation of the safety or efficacy of com-
pounds (Fig. 1). First, it can provide information on biological 
characteristics of the used biological system to understand the 
complexity of the in vitro environment in which the compound 
is studied (Zock, 2009; Scholz et al., 2013). Second, it allows 
multiple phenotypic and functional read-outs that can be inte-
grated to identify dynamic cell responses to toxicants (Herpers 
and van de Water, 2013; Wink et al., 2014; Falsig et al., 2004; 
lund et al., 2005). third it can provide information on com-
pound pharmacology, such as its target, efficacy or potency in a 
screening system (Mulji et al., 2012). Finally, it can be used in 
combination with siRNA libraries or drug-based cell modifica-
in academia, pharmaceutical industry and regulatory bodies with the objective to compile the state- 
of-the-art of the technology in the different institutions. Together they defined technical and 
methodological gaps, proposed quality control measures and performance standards, highlighted cell 
sources and new readouts and discussed future requirements for regulatory implementation. This review 
summarizes the discussion, proposed solutions and recommendations of the specialists contributing  
to the workshop.
Keywords: high content imaging, toxicology, drug development, toxicity pathways, mechanistic safety 
screening
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– the data on the multiple phenotypic and/or functional param-
eters can be integrated and correlated across dose and time to 
establish multiple concentration-response relationships. Com-
parison of these relationships allows the differentiation be-
tween exposures that, e.g., lead to a loss in cell function, alter 
the metabolic state or morphology of a cell or organelle, and 
induce cytotoxicity. the in vitro concentrations at which these 
different events occur can be used to define in vitro bench-
mark concentrations for mechanistic safety assessment.
– The differentiation and study of specific cell sub-populations 
or different organelles in a biological system. the cell sub-
populations can be distinguished based on phenotypic or 
functional characteristics such as cell morphology, matura-
tion, differentiation stage, viability, metabolic state, or cell 
cycle phase. the cellular phenotype that is the most or the 
least vulnerable for the toxicity of a compound can provide 
insight into its MoA. It also creates the opportunity to exclude 
cell phenotypes that are not relevant for toxicological inter-
pretation (e.g., dying cells) to reduce noise and increase the 
sensitivity of an assay.
2.2  Current high content imaging applications  
in safety sciences
High content imaging applications have different levels of com-
plexity depending on the safety questions to be answered (Fig. 
2). the complexity of an assay is mainly determined by the 
choice of the biological system and imaging technology. A va-
riety of in vitro cell systems (cell lines, co-cultures, 3D cell cul-
tures, and stem cells) and lower model organisms (Caenorhab-
ditis elegans, Danio rerio) are available with different levels 
of biological complexity. Gene reporters, fluorescent dyes or 
biosensors for specific cell structures (e.g., membranes, cytosol, 
nucleus, mitochondria, Golgi) or functional processes (e.g., cell 
signaling pathways, transport, and energy metabolism) can be 
visualized for quantification and monitoring over time using 
image analysis software. the data acquisition can be achieved 
using either 2D or 3D imaging technologies. 3D imaging gen-
erates more accurate results on the shape, size, location and 
relationship between cellular structures or processes. An even 
more complex acquisition technology includes the “organ on a 
chip approach,” which uses a 3D microfluidic cell culture chip 
that can both measure and simulate the activities, mechanics and 
physiological responses of entire organs or organ systems (Huh 
et al., 2011; Baker, 2011). Using this approach, multiple biologi-
cal processes, e.g., in the liver, kidney, lung or heart can be stim-
ulated (pharmacologically or mechanically) during the imaging 
data acquisition, which allows the investigation of biological 
mechanisms and responses in organ specific microenvironments 
(Yum et al., 2014). the obtained imaging datasets are analyzed 
using imaging analysis algorithms for the automated unbiased 
extraction of quantitative information. the algorithms can be 
used to discriminate specific target elements in the images such 
as cells, organelles, biological structures and processes. these 
target elements can be traced to define the exact size, shape and 
volume of biological structures (e.g., vasculature, neurites, mi-
crotubules) or tracked over time to show dynamic movements 
of biological processes (e.g., cell migration, differentiation, 
tions to screen targets and MoA of compounds (Krausz, 2007; 
Verissimo et al., 2012; Benedetti et al., 2013).
Within the field of HCI, there are many different assay designs 
that make use of the various biological systems, probes and im-
aging technologies that are currently available. It is difficult to 
define the exact design characteristics (number of cells analyzed 
and read-out parameters) an imaging assay should have to be 
considered as high content, but in general it concerns simultane-
ous measurement of multiple parameters. A number of general 
characteristics of HCI were defined during the workshop. These 
have been summarized in (Box 1). 
Pharmacology
- Target finding
- Efficacy tests
- Characterization of compounds
High Content Imaging
(a technology)
Biology
- Biological structures & processes
- Characterization of biological
systems
- Chemical biology (RNAi screens)
Toxicology
- Mechanistic characterization
- Quantitative phenotypic &
functional readouts
Box 1:  
General characteristics of high content imaging
–  Based on automated imaging technologies
–  Simultaneous read-outs of multiple quantitative parameters
–  Allows the acquisition of temporal and spatial information 
(live cell imaging)
–  Allows the study of effects at subcellular level (e.g., nucleus, 
mitochondria, lysosome, or ER)
–  Allows the differentiation of cell sub-populations in a 
biological system (e.g., healthy vs. dying cells)
–  Makes use of probes or biosensors for specific labeling of 
cellular structures or processes (antibodies, reporters, dyes, 
auto-fluorescence)
–  Applies unbiased and automated image analysis algorithms
Fig. 1: Use of HCI technology in different interrelated fields
High content imaging can provide relevant biological, toxicological 
and pharmacological information to support assay design, 
compound safety assessment and drug discovery.
the value added by a high content imaging approach com-
pared to the conventional single read-out methods includes:
– the unbiased automated imaging of multiple phenotypic and/
or functional parameters in a living biological system, which 
provides insight into the dynamics and spatial distribution of 
biological processes underlying cell homeostasis, defense, 
adaptation, toxicity and death. 
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tiated rat l6 skeletal muscle cells were treated with different 
compounds covering a wide range. Cells were treated for 5 days 
and cell death was measured by tUNel assay as well as by 
assessment of the number of cells present in each well (objects 
count). To assess skeletal muscle specificity of the observed ef-
fects, rat fibroblasts were treated in parallel and cell death was 
measured in the same way as for rat skeletal muscle cells. 
Case study B: the aim of the study was to investigate in 
BAlB/c 3t3 cells mitochondrial toxicity by the non-invasive 
monitoring of bio-energetic activity and redox state using the 
endogenous fluorescing molecules nicotinamide adenine di-
nucleotide (NADH) and flavine adenine dinucleotide (FAD) 
(Bednarkiewicz et al., 2011; Rodrigues et al., 2011). the quan-
tification of NADH and FAD auto-fluorescence can be used 
to determine whether mitochondria are in an active, resting, 
starved, or hypoxic/anoxic state. the transition between active 
and resting state can be used as a tool to detect the very early 
reversible changes in cell bioenergetics. If a compound induces 
injury the mitochondria will lose their membrane potential. this 
process will be detected by the conversion of mitochondrial 
NADH from its reduced fluorescing form to the non-fluorescing 
oxidized form. Positive controls for cytotoxicity were sodium 
lauryl sulfate and HgCl2. the time from the application of the 
compound to the drop in NADH fluorescence decreased with 
increasing concentrations of the compound. this allowed the 
establishment of highly sensitive concentration-response rela-
tionships for mitochondrial toxicity.
Case study C: the aim of the study was to investigate drug-
induced injury using parallel live cell time-lapse imaging of oxi-
dative stress reporters in engineered HepG2 cells (Wink et al., 
2014). In addition, because cellular stress responses typically 
follow cell perturbations at the sub-cellular organelle level, the 
oxidative stress monitoring was complemented with reporters 
for specific cell organelles to determine their morphometry and 
function. Oxidative stress was monitored using reporters for the 
neurite outgrowth) (Shariff et al., 2010). Specific alterations in 
the structure or behavior of target elements can be identified 
as biomarkers for toxicity (Blaauboer et al., 2012) or MoAs of 
compounds.
to verify the involvement of particular cell signaling mol-
ecules, genes, proteins or metabolites in biological processes or 
responses, gene silencing technologies such as RNA interfer-
ence (RNAi) or biochemical inhibitors (antagonist) are often 
used to inhibit cell-signaling pathways. For toxicity studies, 
concentration response relationships for the phenotypic and/or 
functional read-outs are used to identify benchmark concentra-
tions that induce molecular initiating events or induce pathways 
leading to cell adaptation and toxicity. the in vitro benchmark 
concentrations can be extrapolated to a dose for comparison 
with existing in vivo or human data (Yoon et al., 2012; leist et 
al., 2012). An important feature of high content screening is that 
the effects of a compound can also be studied in human cells 
(e.g., differentiated human stem cells), which is highly relevant 
information for the safety assessment of drug development. 
2.3  High content imaging case studies 
Major factors that define biological relevance of HCI include 
the complexity of the used biological system, the presence of 
different cell types and the choice and number of mechanistic 
read-outs (Fig. 3). During the workshop state-of-the-art HCI 
studies performed either in academia, industry or regulatory re-
search centers were discussed. Five examples of case studies 
(indicated in Fig. 3) with increasing levels of complexity are 
described below.
Case study A (unpublished observation of participants): the 
aim of the study was to investigate the potential liability of dif-
ferent drug candidates to induce toxicity in rat skeletal muscle. 
Rat skeletal muscle cell cultures were based on the l6 myoblast 
cell line. Immature myoblast cells were differentiated until fu-
sion to myotubes was observed in vitro. Afterwards, differen-
Primary cells, cell lines , co-cultures, stem cells, 3D cell models, lower
organisms (e.g. C. elegans, zebrafish)
Reporters / dyes / biosensors
Cytosol Mito. Membranes Nucleus Neurites
2D/3D Tracing Co-localization
- DNA / RNA
- Transcription factors
- Enzymes and receptors
- Metabolites
- Potential differences, pH
Examples
Cell source:
Readouts:
Cell/compartments:
Spatial imaging:
Imaging targets:
Whole cell
Segmentation
Fig. 2: HCI has a broad application range
High content imaging approaches have different levels of 
complexity depending on the biological system, readouts, cell 
type/compartments, imaging space and target of interest  
(Mito.: Mitochondria).
Complexity of HCI approach
Re
ad
 ou
ts
A
B
C
Fixed cells Living cells Time/kinetics 3D
D
E
Fig. 3: Potential of HCI
High content imaging assays can have different levels of 
complexity or numbers of read-outs, and cell types. The ideal HCI 
approach uses the simplest approach that is sufficient to answer 
the biological question. The points A, B, C, D and E refer to 
examples, i.e. the case studies described in the text. 
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increasingly sophisticated image analysis algorithms. Neverthe-
less there remain significant gaps and challenges to be over-
come to fully exploit the potential of the technology in safety 
sciences (Zanella et al., 2010; Bickle, 2010).
3.1  Technical limitations 
the applicability of imaging systems for more complex biologi-
cal systems such as 3-dimensional cell models (e.g., floating 
spheroids) is still limited by the depth of light penetration and 
diffusion of probes. the requirement for attached cells is also 
still a limitation for routine applications and fluorescence acti-
vated cell sorting (FACS) is the preferred method in this case. 
Complications arise, e.g., when adherent cells detach during cell 
death processes (leist et al., 1996; Falsig et al., 2004). Under 
such circumstances, microscopic methods need to include time-
lapse imaging with very complex quantification techniques and 
therefore biochemical methods are still superior.
the limited availability of reporters, probes and biosensors for 
the visualization and quantification of cell signaling pathways 
restricts the design of functional HCI assays. this also concerns 
the number of probes that can be introduced in a biological sys-
tem and can be simultaneously measured and distinguished us-
ing different channels (e.g., based on signal wavelengths). 
Standard HCI software is still limited with respect to the com-
bination of selection criteria for cells. Often large numbers of 
cells are excluded in the analysis. For example, complex cells or 
cell phenotypes that are easily scored by semi-manual methods 
(Gerhardt et al., 2001; Volbracht et al., 1999; Hansson et al., 
2000) are hard to recognize for the software. this applies often 
when cells undergo morphological changes, for example as they 
occur in phagocytosis assays (Hirt et al., 2000) or when using 
cytochrome c release as endpoint (latta et al., 2000).
3.2  Scientific relevance and standardization  
of the biological system 
For HCI, as for other analytical approaches, it is critical to se-
lect and characterize a biological system that is scientifically 
relevant for the purpose of the assay. the morphological (cell 
types, structures, receptors) and functional (signaling pathways, 
metabolism, transport) phenotype of the biological system must 
be sufficiently characterized to make sure it is relevant for the 
effects to be studied. For example, for the study of compounds 
that require cell-cell interactions or metabolism to exert their 
toxicity, a biological system with the appropriate cell types and 
metabolic capacity must be selected (Gantner et al., 1996). As 
safety sciences are moving towards mode-of-action investiga-
tions in increasingly complex biological systems, such charac-
terization steps will become more important. Besides charac-
terization, the biological system should be well standardized 
to guarantee the scientific relevance and reproducibility of the 
obtained results. therefore, the health condition, purity and 
dynamic range of biological response of a biological system 
should be regularly controlled using reference compounds with 
a well known effect. Historical data on reference compounds 
can be used to define performance standards for biological sys-
tems and measurements (Wind and Stokes, 2010; leist et al., 
2010; Smirnova et al., 2014).
oxidative stress sensor Keap1, the transcription factor Nrf2 and 
the antioxidant enzyme sulfiredoxin-1 (Srxn1). After exposure to 
the positive control iodoacetamide, Keap1 accumulation in foci 
(identified as autophagosomes). This was followed by the trans-
location of Nrf2 to the nucleus. Several hours later, these events 
were followed by a strong increase in the levels of Srxn1. thus, 
the combination of oxidative stress and cell organelle reporter 
read-outs was able to detect different events of cellular malfunc-
tioning on a single-cell basis, prior to the onset of cytotoxicity. 
Case study D (unpublished observation of participants): the 
aim of the study was to investigate whether compounds induce 
liver toxicity by affecting either primary hepatocytes or Kupffer 
cells or both and in addition to measure Kupffer cell phago-
cytosis. Hepatocytes and Kupffer cells were co-cultured and 
treated with a compound at different concentrations for 48 h. 
then, Kupffer cells were stained for F4/80 and hepatocytes for 
albumin. Additionally, Kupffer cell phagocytic activity was as-
sessed in parallel by the addition of latex beads labelled with a 
fluorochrome. Cytotoxicity was measured by using a combina-
tion of propidium iodide and calcein-AM. the assay differenti-
ated direct cytotoxicity in hepatocytes or Kupffer cells and ad-
ditionally could measure Kupffer cell phagocytosis by uptake of 
latex beads into Kupffer cells. the combination of the read-outs 
informed on complex interactions of hepatocytes and Kupffer 
cells with regard to their cell type specific functions.
Case study e: the aim of the study was to investigate if the in 
vitro assessment of multiple cardiomyocyte physiological param-
eters enables predictive and mechanistically interpretable evalu-
ation of cardiotoxicity at high throughput level (Sirenko et al., 
2013). Human iPSC-derived cardiomyocytes were exposed for 
30 min or 24 h to 131 drugs (incl. positives and negatives). Fast 
kinetic imaging was used to monitor changes in cardiomyocyte 
function using intracellular Ca2+ flux read-outs synchronous with 
beating and cell viability. A number of physiological parameters 
of cardiomyocyte beating, such as beat rate, peak shape (ampli-
tude, width, raise, decay, etc.) and regularity were collected us-
ing automated image analysis. Concentration-response profiles 
were evaluated using logistic modeling to derive a benchmark 
concentration (BMC). BMC values were used for cardiotoxicity 
classification and ranking of compounds. The assay showed that 
beat rate and several peak shape parameters were good predic-
tors, while cell viability had poor classification accuracy. In addi-
tion, a toxicological prioritization index approach was applied to 
integrate and display data across many collected parameters, to 
derive “cardiosafety” ranking of tested compounds. thus multi-
parametric functional screening of beating profiles allowed for 
cardiotoxicity hazard assessment and identification of specific 
patterns defining mechanism-specific effects.
3  Current gaps and challenges for high content 
imaging approaches
High content imaging technologies have advanced considerably 
over the last years. technological developments that have fa-
cilitated these advances include the development of improved 
automated microscopes (auto-focusing, sample positioning) and 
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bind to cell membranes, accumulate in the cytoplasm or in 
specific subcellular organelles. The distribution of compounds 
in different cell organelles is not well known, because meas-
urements require highly sensitive technologies. Nonetheless, 
this type of information would be particularly valuable for the 
field of HCI because it allows the study of effects on subcellu-
lar structures (e.g., mitochondria, lysosome, eR). In addition, 
the presence of drug transport proteins such as P-glycoprotein 
(PGP), which can actively transport (extrusion) compounds 
3.3  Lack of widely recognized reference 
compounds
the dearth of widely recognized reference compounds to con-
trol the scientific relevance and technical reproducibility of HCI 
assays is one of the major gaps in the field. There is a need for 
a database with reference compounds that have a well-charac-
terized effect on the phenotype or function of a certain biologi-
cal system. these compounds would not only serve as internal 
assay control, but also provide the means to compare the cel-
lular response across laboratories and institutions (Kadereit et 
al., 2012). An important role of such endpoint-specific control 
compounds (Leist et al., 2010) is to determine the specificity 
of the observed toxicity for a particular target or pathway. Dur-
ing the workshop, the participants compiled an example list of 
reference compounds for their respective assays (see tab. 1) to 
initiate the process of closing this gap.
3.4  Concentration issues 
A limitation for HCI and in vitro toxicity studies in general is 
that the true concentrations of a given test compound in a bio-
logical system are not known (Blaauboer et al., 2012). When a 
certain concentration (nominal) of a compound is added to an in 
vitro system, a part of the compound will be bound, e.g., to the 
proteins in the cell culture media (e.g., serum) and the plastic 
of the cell culture dish (Kramer et al., 2012). the compound 
that remains unbound will represent the free concentration to 
which the cell system is exposed (Fig. 4). For chronic toxic-
ity studies the treatment protocol often includes the addition of 
multiple doses via changes of the cell culture media. Depending 
on the nature of the compound and the metabolic capacity of 
the biological system, the compound and/or its metabolites can 
accumulate in the cell system and lead to higher treatment con-
centrations than anticipated. this accumulative effect can result 
in toxicity over-predictions for a compound. 
the distribution of a particular compound in the biological 
system is even more complex. Related to its physical-chemical 
properties (e.g., hydrophilic or lipophilic) a compound can 
Tab. 1: List of compiled reference compounds with well-known biological effects 
Examples for reference compounds Effect
Gambogic acid, camptothecin, staurosporine, actinomycin D Apoptosis
Classical ETC inhibitors: Rotenone, antimycin A, oligomycin  Mitochondrial respiration 
Classical uncouplers: FCCP, CCCP  
Others: troglitazone, simvastatin, valproic acid, amineptine 
IL-1α, IL-1β,TNF-α, PDGF NF-κB signaling
PGA2, sulforaphane, iodacetamide, 3H-1, 2-dithiole-3-thione (D3T),  Keap1/Nrf2 stress response 
tert-butylhydroquinone (tBHQ) 
SU6656, okadaic acid (phosphatase inhibitor), colchicine, NO-donors,  Neurodegeneration 
MG 132 (proteasome inhibitor)
Amiodarone, propranolol, citalopram Phospholipidosis
Tunicamycin (perturbs protein glycosylation), thapsigargin (disruption of ER calcium),  ER stress (ATF-4 responses, XBP1-responses) 
brefeldin A (perturbs protein transport), 
CsA, ATF-4, XBP1
Menadione, tert-butylhydroperoxide DNA damage
Free drug
concentration
Bound away
(plastic, protein, etc.)
Nominal drug
concentration
Distribution
Accumulation
Extrusion
Fig. 4: Relationship between nominal compound 
concentrations in HCI assays and concentrations of  
test compounds in cells
When a nominal concentration of a compound is added to an  
in vitro system, a part of it will be bound and the cell is exposed to 
the unbound free concentration. The concentration of a compound 
in a cell or cell system will depend on its physical-chemical 
properties and the biological characteristics of the cell systems 
(e.g., cell metabolism and transport). 
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curves can be plotted for different cell types or cell populations 
in a biological system. the in vitro benchmark concentrations 
for the multiple read-outs can also be combined, e.g., by calcu-
lation of ratios. For safety assessment, the in vitro benchmark 
concentrations can be extrapolated to a dose and compared to 
in vivo or clinical benchmarks (e.g., in biofluids or tissue). A 
big challenge for the use of benchmark concentrations from 
HCI assays is how to weigh the importance of the different 
read-outs.
3.6  Imaging of dynamic responses
Although the processes in a biological system are dynamic, 
most of the endpoints used in safety sciences are based on 
the strength of a perturbation instead of its dynamics. High 
content imaging in living biological systems using time-lapse 
microscopy can provide information on both the strength and 
dynamics (e.g., frequency) of biological responses over time. 
Because compounds can change the dynamics of biological 
processes instead of the strength, the study of dynamics can 
be essential for mode-of-action identifications. Figure 6 pro-
vides an example of a normal versus a toxicity response with 
an identical strength represented by the area under the curve 
(AUC 1 = AUC 2), but with different dynamics (frequency). 
the difference between these two responses would be identi-
fied by endpoints measuring their dynamics over time, but not 
by their strength (= average increase) at a given time point. 
Dynamics are particularly important for functional assays and 
they occur on very different time scales. For example, NF-κB 
translocation has a low frequency (hours) compared to calcium 
out of a cell, plays a role in the distribution of a compound 
in a biological system. the technologies required to measure 
true concentrations of compounds in a cell or cell system (e.g., 
imaging or mass spectrometry) are still under development 
and not available for routine studies. techniques that combine 
mass spectrometry and imaging techniques (matrix-assisted 
laser desorption/ionization, secondary ion mass spectrometry 
(SIMS) and nanoSIMS) are promising (Dollery, 2013). Be-
cause there is a major need to define true concentrations in in 
vitro systems, more efforts are required to develop and stand-
ardize the required technologies. 
3.5  Benchmarking of high content imaging data
A particular added value of the high content imaging approach 
is that it allows comparisons of concentration-response rela-
tionships for multiple phenotypic and functional read-outs in 
a biological system (see Fig. 5). the concentrations that affect 
cell function can be distinguished from those that induce cy-
totoxicity. In a functional assay, the size of the off-set between 
functional endpoint and cytotoxicity is an important charac-
teristic to demonstrate the relevance of the obtained results. 
A large off-set shows that a compound specifically affects cell 
function. Using reference compounds with a standardized off-
set in a biological system, a functional assay can be validated. 
the concentrations at which the in vitro read-outs are affected 
can be used as benchmark concentrations (BMC). these BMCs 
can also be established for different sub-populations of cells in 
a biological system or in different cell organelles (Veronika 
et al., 2009). Consequently, multiple concentration response-
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Fig. 5: The relationship between functional and cytotoxicity 
readouts of an HCI assay
The plotting of multiple concentration response curves from 
functional and cytotoxicity read-outs allows the determination 
of benchmark concentrations (BMC), such as the EC20. Also, 
the Lowest Observed Effect Concentration (LOEC) and IC50 
concentrations can be determined and used. The benchmark 
response in the figure was set arbitrarily to 20%, in other cases, 
10 or 15% could be more relevant depending on the read-out 
parameters.
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Fig. 6: Imaging of dynamic responses
The added value of imaging response dynamics is that it provides 
information on both the frequency and amplitude of a biological 
response. Although the amplitude of two responses can be 
identical in the area under the curve (AUC), their frequency can be 
changed by an exposure. 
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4  Quality control and performance standards 
Quality control measures and performance standards are a high-
ly important but neglected area, not just for HCI but also for 
other modern approaches (Ramirez et al., 2013; Basketter et al., 
2012; leist et al., 2010). 
A preparation of guidelines was highly recommended by the 
participants of the workshop to improve the quality and re-
producibility of HCI data, and to facilitate comparison of data 
between institutions. As a first step, the participants proposed 
to establish guidance for the reporting of HCI studies in the 
scientific literature (Tab. 2). Currently, the settings of the in-
strumentation and details of data analysis are often not pro-
vided in publications. this makes it impossible to reproduce a 
study. Some basic guidance on scientific reporting would help 
to fully understand the design of assays and to reproduce re-
sults. A framework for quality control measures and perform-
ance standards discussed during the workshop is summarized 
in table 3. 
5  Data analysis and integration of read-out 
parameters
HCI can be used as (i) a hypothesis driven approach that aims 
to confirm a predefined MoA by the quantification of related 
mechanistic parameters or (ii) as an unsupervised hypothesis 
generating approach that aims to identify a mechanism/MoA 
by the unbiased quantitative screening of multiple mechanis-
tic parameters that cover different MoAs. For the former ap-
proach, the levels of the predefined mechanistic parameters 
are measured and compared to identify statistically significant 
up or down regulations by a compound. To confirm the hy-
pothesis (e.g., MoA), siRNA or pharmacological antagonists 
can be applied to test whether the toxicity occurs when the 
mechanism(s) is inhibited or blocked. the screening approach 
usually involves much larger datasets. Because the importance 
or weight of the different readout parameters is not know, it 
can be challenging to create a reduced index with the most 
relevant parameters. Unsupervised data mining techniques are 
often applied (e.g., principal component analysis or linear dis-
fluxes (seconds). Therefore, it is important to consider the time 
resolutions of the functional read-outs during the design of an 
assay in order to pick up all the dynamics of the response. An-
other example where dynamics play an important role is cell 
cycle analysis, as different phases occur over time. 
the range of interest in which the toxicity mechanisms of a 
compound can be studied is dependent on the time scale (acute 
or chronic effects) as well as the concentration range (Fig. 7). 
the range of interest starts with the biological system at home-
ostasis and ends at the induction of cell death, which provides 
no additional mechanistic information on MoA. Different 
exposure scenarios can yield broader information on toxicity 
than only a single standard approach, and the set of conditions 
needs to be adapted to the types of endpoints chosen.
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Fig. 7: Overview of exposure scenarios that can be  
addressed specifically (white) or that result in unspecific  
cell death (grey)
Phenotypic and functional read-outs within this range of interest 
can provide mechanistic insight into the response of a biological 
system after exposure to a compound.
Tab. 2: Guidelines for the reporting of high content imaging results
Aspect of the study Information required
Instrument settings – All settings need documentation in a form that is platform-independent (as far as possible).
Biological system – Biological relevance needs to be justified. 
 – Labeling procedures need comprehensive description. 
 – Assay conditions and treatments need sufficient detail to allow reproduction.
Readout parameters – Scientific relevance needs justification and validation by control compounds. 
 – Dynamic range of measurement (time) needs full exploration.
Image analysis – Define algorithms independent of commercial platform used. 
 – Inclusion and exclusion criteria for imaging targets with documentation by example images  
    need to be defined.
Data analysis – Statistics need to be applied. 
 – Number of imaged targets (cells, organelles, pathways, etc.) needs to be documented.
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nologies are particularly useful for the identification of genes, 
proteins and metabolites involved in the mechanistic pathways 
underlying cell defense, adaptation and toxicity. High content 
imaging in living cells using time-lapse microscopy can be 
used to monitor the spatial distribution and dynamics of the 
identified pathways to identify the switch-points between bio-
logical processes, e.g., from homeostasis, to the activation of 
criminant analysis) to identify the parameters with the largest 
contribution or weight. the next challenge is the integration of 
the identified parameters to generate a hypothesis on the MoA 
of a compound. Data integration software coupled with data-
bases on fundamental biological processes can be used to cor-
relate the response of the individual parameters and link them 
in functional networks and cell signaling processes. to support 
the analysis and integration of HCI data it would be useful to 
establish reference databases with information on the biologi-
cal relevance and mechanistic relationships between read-out 
parameters. Such a database could be linked to HCI software 
that automatically integrates and links multiple read-out pa-
rameters with biological information to confirm or generate a 
hypothesis on the MoA of a compound.
6  Integration of high content imaging with other 
technologies
Supported by the advances in informatics and data analysis 
technologies, the field of safety sciences is moving towards a 
systems biology approach that aims to integrate data from dif-
ferent technologies to obtain a systems level understanding of 
the mechanistic pathways underlying cell adaptation and tox-
icity (van Vliet, 2011; Hartung et al., 2012). the focus in the 
area of systems biology is mostly on omics technologies be-
cause they provide comprehensive information on the genome, 
proteome or metabolome of a biological system (Waldmann et 
al., 2014; Wink et al., 2014; Sturla et al., 2014). However, in-
formation on the dynamics over time can be required to under-
stand the MoA of a compound. therefore, HCI can be a valu-
able technology to complement the systems biology approach 
with information on the spatial distribution and dynamics of 
biological processes and responses (see Fig. 8). Omics tech-
Tab. 3: Overview of proposed quality control and performance standards
Requirements Proposed solutions
Instrument calibration Control of the read-out settings and dynamic range of the assay using a standardized kit  
 that includes cells labeled for multiple parameters.
Image analysis calibration Calibration of image analysis algorithms by the analysis of a set of widely accepted  
 reference images.
Biological controls Control of the biological relevance, health status and dynamic response of the biological  
 system using a library of widely accepted positive and negative reference compounds.
Toxicity controls Control of the specificity of the toxic effects for a particular target (e.g., receptor,  
 cell type, organelle, organ) using reference compounds, gene silencing approaches or  
 pharmacological inhibitors. 
Data controls Deposit of data in databases and opportunity for review by independent labs.
Data handling and analysis guidelines Guidelines for data storage, analysis and sharing via databases should be developed,  
 giving transparency as to which guidelines have been followed.
Performance standards Establishment of performance standards based on historical data on:  
 – Number of cells that need to be analyzed 
 – Dynamic range 
 – Reproducibility of results 
 – Sensitivity and specificity for reference compounds
Genomics
Proteomics Metabolomics
HCI
System disturbance:
homeostasis-defense-adaptation-toxicity
snapshots
Time-lapse
HCI
Systems biology
(Pathways of toxicity & networks)
Inter-
ference
HCI
(screen of
siRNA,
inhibition
libraries)
Fig. 8: Integration of HCI with other technologies
Time-lapse high content imaging in living cells and interference 
high content screening using siRNA can complement the systems 
biology approach with information on the spatial distribution and 
dynamics of pathways and by validating the pathways of toxicity. 
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tions that induce mechanisms of cell defense, adaptation and 
toxicity in different compartments of a cell, cell type or cell 
system. Complex biological systems, such as organ-on-a-chip 
models that closely reproduce the in vivo microenvironment, 
will offer new opportunities for the study of long-term toxic-
ity of low concentrations in organ and multiple organ systems. 
Because these systems provide novel opportunities to stimulate 
the organ using mechanic force or pharmacological tools, they 
will create opportunities to image specific perturbations under 
controlled conditions. 
7.2  Inclusion of high content imaging in  
the design of testing batteries and strategies
It is generally recognized that the safety of a compound can-
not be based on a single in vitro assay. therefore, scientists are 
working on the design of testing batteries and coupled strategies 
(Hartung et al., 2013). A testing strategy involves, e.g., tiered 
testing with interim decisions between assays, for example by 
testing only negative or positive compounds (hits) in the next 
assay. Due to the variety of phenotypic and functional endpoints 
that can be measured, HCI assays can be valuable for the design 
of testing strategies. tailored HCI assays based an animal or 
human cell models could be strategically combined to identify 
hits for a number of pre-defined phenotypic and functional end-
points (see Fig. 10). For example, for drug development a test-
ing strategy for different target organ functions at non-cytotoxic 
concentrations could be designed for the safety screening and 
ranking of lead compounds. the strategy design could be based 
on functional read-outs for liver toxicity (e.g., phospholipidosis, 
cholestasis, steatosis), neurotoxicity (e.g., neurite outgrowth, 
neurotransmission) and cardiotoxicity (e.g., contractility, Ca2+ 
flux readouts). Compounds that affect a functional read-out 
could be identified as a hit and be further investigated. The 
concentration-dependence of the different endpoints could also 
give first indications on organ toxicity.
cell defense mechanisms, cellular adaptation and induction of 
toxicity. In addition the high content screening based on siR-
NA libraries allows the confirmation of pathways for a toxic 
effect (Fredriksson et al., 2011; Verissimo et al., 2012), iden-
tification of alternate pathways and the interaction between 
different pathways in the system. the inclusion of dynamic 
information (monitoring of read-out levels over exposure time 
and concentration range) into the systems biology approach 
also supports the modeling of benchmark concentrations for 
safety assessment. 
7  Future perspectives 
7.1  Future potential of high content imaging  
for safety sciences
Although high content imaging currently plays an important 
role in safety sciences (Fig. 9), the application of the technol-
ogy is expected to increase further, as safety studies are in-
creasingly focused on MoA (Andersen and Krewski, 2009). At 
present, HCI technologies are often used to patch knowledge 
gaps (e.g., to confirm the mechanism of an in vivo effect) using 
tailored multi-parametric and functional assays. In fact, gen-
eral scientific progress in toxicology is still largely based on the 
patching of knowledge gaps and replacement of a single tech-
nology with an improved one, despite suggestions to re-think 
the overall approach and re-design it from scratch (leist et al., 
2008, 2012; Hartung, 2009; Basketter et al., 2012). More work 
is required on how to integrate HCI data with data from other 
assays and other emerging technologies (e.g., omics, in silico 
tools, organ-on-a-chip) to create a systems biology approach. 
Moreover the integration of HCI data with information on free 
and cellular concentrations in the biological system (e.g., using 
SIMS imaging technologies) would be particularly promising, 
as it could generate very accurate information on the concentra-
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(e.g., in human cells)
Multi-parametric assays
Functional assays
Integration with other
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Systems for organ toxicity
& long-term stability
Spatial distribution of
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Fig. 9: State of the art and future developments of HCI  
in the field of safety sciences and drug discovery
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Fig. 10: Tailored high content imaging assays can be 
combined in a testing strategy to efficiently identify hits  
for multiple functional endpoints
Different functional perturbations can be measured by HCI at 
concentrations or exposure conditions that do not trigger cell 
death. 
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would gain experience with the technology themselves to build 
confidence in the information it can provide. As an initial step, it 
may be useful to integrate HCI technologies into the regulatory 
framework for MoA identifications. This could be done, for ex-
ample, by using HCI readouts to link molecular level data to the 
resulting alteration in cellular function and phenotype. the in-
formation on MoA and compound behavior can also support the 
weight of evidence approach for regulatory decision-making. 
At this point it is most crucial to design guidance for the quality 
assurance and validation of HCI technologies.
8  Conclusions 
With the current focus of toxicology on the understanding of 
toxicity pathways in (human) cell systems and mechanistic 
safety assessment, the role of HCI technologies is likely to in-
crease further (leist et al., 2008; Andersen and Krewski, 2009; 
Krewski et al., 2010; Berg et al., 2011; van Vliet, 2011). to fully 
exploit the potential of HCI, there are still some remaining gaps 
and challenges to be overcome (Box 2). to increase the scientif-
ic relevance of HCI data for the in vivo and human situation, the 
technology must be tailored for the analysis of more complex 
biological systems such as 3D cell models (Wenzel et al., 2014) 
and human stem cell models (Barbaric et al., 2010; Sherman 
et al., 2011). For this, it is also necessary to develop additional 
probes and biosensors to label, monitor and quantify multiple 
functional processes in biological systems without interference. 
Moreover, data quality and reproducibility would benefit from 
the establishment of widely accepted control measures and per-
formance standards in the field. For the design of HCI assays it 
is important to test the scientific relevance and stability of the 
biological system using reference compounds that induce well-
characterized perturbations. At the same time more knowledge 
is required on the exact concentrations of compounds (free and 
bound) in cell culture systems and their distribution at the sub-
cellular level. Ideally the concentration of compounds in cells or 
cell organelles could be quantified during HCI studies to allow 
more accurate predictions of in vitro benchmark concentration 
7.3  Development of HCI computational database 
systems for “Big Data”
HCI data can be used to establish toxicity profiles for com-
pounds. The profiles within a research institution or among dif-
ferent institutions could be gathered in computational database 
systems (Big Data) according to strict guidelines for data rel-
evance and quality. Such efforts have already been initiated by 
toxCast (Kleinstreuer et al., 2014), the tox21 programs (Zang 
et al., 2013) and within the toxBank project of SeURAt-1 
(toxbank.net). Once the database contains a critical number of 
compounds and read-out parameters (incl. reference compounds 
for specific MoA and organ toxicities) the HCI profiles could be 
compared for the hierarchical ranking of new compounds ac-
cording to their potency, hazard, efficacy or MoA (see Fig. 11) 
in a quantitative read across approach. In addition, the multi-
ple read-outs could be ranked according to their specificity and 
sensitivity for specific toxic effects. Such a database would be 
particularly useful for industry and regulatory bodies to priori-
tize compounds and read-out parameters for safety assessment 
and drug development. this could form the basis for a new ap-
proach to the study of systemic and long-term chronic effects at 
low concentrations (e.g., liver toxicity). Moreover, animal stud-
ies could be made more efficient by the pre-selection of highly 
specific and sensitive read-out parameters. The database could 
also be used to predict the mechanisms or classify unknown 
compounds, by comparing their HCI profile to the profiles of 
the compounds in the database. Besides HCI data other types 
of information could eventually be introduced in the database, 
e.g., in silico data based on physiochemical or pharmacokinetic 
properties of compounds, which also determine their bioavail-
ability and the interaction with cellular structures (binding to 
membranes, receptors, proteins, cell organelles). 
7.4  Regulatory acceptance of high content imaging
the application of high content imaging in safety sciences would 
significantly advance, if its results were also used for regulatory 
purposes. to achieve this, HCI assays would need to be validat-
ed and accepted by regulatory agencies. Ideally, the regulators 
Fig. 11: Use of HCI profiles of 
multiple assays across time and 
concentrations for compound 
profiling and read across
Compounds can be grouped according 
to mechanistic similarity and be ranked 
within groups for potency.
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for toxicity or efficacy of drug compounds. Because HCI pro-
vides concentration-response information on multiple pheno-
typic and functional read-outs, novel composite endpoints may 
be established to allow more specific predictions (Perkins et al., 
2013). For compounds that require information on dynamics or 
spatial distribution for safety assessment (e.g., temporary mor-
phometric effects or metabolism related effects), HCI data using 
time-lapse microscopy can be applied to generate dynamic and 
spatial profiles of biological responses. As the extrapolation of 
in vitro data from traditional single quantitative readouts is al-
ready a challenging task, more research is required on how data 
on dynamics and spatial distribution could be integrated.  
Box 2: 
Recommendations
To further exploit the potential of high content imaging in the 
field of safety sciences, the workshop participants made the 
following recommendations:
–  High content imaging assays need to be more focused on 
multiple functional read-outs in biological systems instead 
of measuring cytotoxicity parameters in relatively simple cell 
lines. More applications need to be developed for labeling of 
complex or 3D biological structures and functional processes 
for live cell imaging.
–  Besides the study of acute effects, more studies are required 
that address chronic toxicity of low-level exposures in 
biological systems with a long-term stability, such as “organ-
on-a-chip” approaches.
–  More data mining studies are required that demonstrate the 
added value of integrating the multiple read-out parameters 
of high content imaging assays and data from other 
technologies to identify interactions between biomolecules 
and pathways underlying cell defense, adaptation and 
toxicity.
–  New toxicity benchmarks need to be explored for high 
content imaging data based on the concentration response 
data from multiple read-outs in a biological system or 
systems. Such benchmarks could consider both the 
frequency and amplitude of responses over time (dynamics), 
the ratios between responses and concentration offsets 
between phenotypic and functional read-outs.
–  Actual gaps for the regulatory use of high content imaging 
need to be identified and patched. Quality control measures 
and performance standards are a necessary prediction for all 
further steps.
–  One of the most critical issues for high content imaging and 
the entire field of in vitro toxicology is the determination of 
true concentrations (free and bound) in in vitro systems and 
their extrapolation to in vivo doses.
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